SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0195 668X "

Sökning: L773:0195 668X

  • Resultat 41-50 av 2139
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  •  
42.
  •  
43.
  • Aburawi, Elhadi, et al. (författare)
  • Relation of aortic root dilatation and age in Marfan's syndrome
  • 2007
  • Ingår i: European Heart Journal. - : Oxford University Press (OUP). - 1522-9645 .- 0195-668X. ; 28:3, s. 376-379
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims The main aim of this study was to describe the age at which pathological aortic root dilation occurs in patients with Marfan's syndrome (MFS). Methods and results A total of 160 patients with MFS attending a regional cardiac centre were reviewed retrospectively. Dilation of the ascending aorta was diagnosed by comparing the maximum aortic sinus measurement with control data from the literature. We employed a Kaplan-Meier survival curve to estimate the age at which dilatation occurs. The mean age of the total group at presentation was 15.5 years (range 1.5-40 years). Skeletal abnormalities were present in 95%. Eye involvement was found in 18%. In the 115/160 patients with an abnormal aortic root, 78/115 (68%) developed aortic root dilatation before 19 years of age. From the Kaplan-Meier curve, it can be estimated that about 35% of the patients have aortic root dilatation already at the age of 5 years and 70% before the age of 20 years, and at least 80% by 40 years. There were 31 patients with normal aortic root when first seen but 24/31 (77%) developed aortic root dilatation before the age of 19 years and 7/31 (22.6%) after 19 years of age. Of those (seven patients) who developed new pathological aortic root dilatation after age 19 years, the age range was between 21 and 40 years with a mean of 27 years. Overall, 13 patients (8%) had surgery for aortic root replacement. Conclusion Aortic root dilatation develops early in MFS and was present in 35% by the age of 5 years and 68% by 19 years. Even though new aortic root dilation is relatively rare, it is not possible to safely discharge patients with MFS as about one-third of the patients in our series who developed new pathological aortic root dilation did so after the age of 19 years.
  •  
44.
  •  
45.
  •  
46.
  •  
47.
  • Adamson, Carly, et al. (författare)
  • Dapagliflozin for Heart Failure According to Body Mass Index : The DELIVER Trial.
  • 2022
  • Ingår i: European heart journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 43:41, s. 4406-4417
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important. The effects of dapagliflozin were examined according to body mass index (BMI) among patients in the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure trial. METHODS AND RESULTS: Body mass index was analysed by World Health Organization (WHO) categories and as a continuous variable using restricted cubic splines. Body mass index ranged from 15.2 to 50 kg/m2 with a mean value of 29.8 (standard deviation +/- 6.1) kg/m2. The proportions, by WHO category, were: normal weight 1343 (21.5%); overweight 2073 (33.1%); Class I obesity 1574 (25.2%); Class II obesity 798 (12.8%); and Class III obesity 415 (6.6%). Compared with placebo, dapagliflozin reduced the risk of the primary outcome to a similar extent across these categories: hazard ratio (95% confidence interval): 0.89 (0.69-1.15), 0.87 (0.70-1.08), 0.74 (0.58-0.93), 0.78 (0.57-1.08), and 0.72 (0.47-1.08), respectively (P-interaction = 0.82). The placebo-corrected change in Kansas City Cardiomyopathy Questionnaire total symptom score with dapagliflozin at 8 months was: 0.9 (-1.1, 2.8), 2.5 (0.8, 4.1), 1.9 (-0.1, 3.8), 2.7 (-0.5, 5.8), and 8.6 (4.0, 13.2) points, respectively (P-interaction = 0.03). The placebo-corrected change in weight at 12 months was: -0.88 (-1.28, -0.47), -0.65 (-1.04, -0.26), -1.42 (-1.89, -0.94), -1.17 (-1.94, -0.40), and -2.50 (-4.4, -0.64) kg (P-interaction = 0.002). CONCLUSIONS: Obesity is common in patients with HFpEF and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.
  •  
48.
  •  
49.
  •  
50.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-50 av 2139
Typ av publikation
tidskriftsartikel (1285)
konferensbidrag (817)
forskningsöversikt (35)
annan publikation (2)
Typ av innehåll
övrigt vetenskapligt/konstnärligt (1145)
refereegranskat (994)
Författare/redaktör
Rydén, L. (118)
Jernberg, T (96)
Wallentin, Lars (81)
Swedberg, Karl, 1944 (67)
Wallentin, Lars, 194 ... (64)
Pernow, J (56)
visa fler...
Cosentino, F (55)
Linde, C (55)
Agewall, S (54)
Erlinge, D. (43)
Braunschweig, F (40)
Norhammar, A. (40)
Malmberg, K (39)
Lund, LH (38)
Rosenqvist, M (37)
Lindahl, Bertil (37)
de Faire, U (35)
Edner, M (33)
Lindahl, B (31)
Dahlstrom, U (30)
Wallentin, L (29)
Savarese, G (28)
James, Stefan (28)
Herlitz, Johan (27)
Siegbahn, Agneta (27)
Rosengren, Annika, 1 ... (27)
Sylven, C (27)
Friberg, L. (27)
Paneni, F. (27)
Gigante, B (27)
Hjemdahl, P (26)
Granger, C. B. (26)
Persson, H (26)
James, Stefan, 1964- (26)
Hamsten, A (26)
Erlinge, David (25)
Hansson, GK (25)
Komajda, M. (24)
Svensson, P (23)
Al-Khalili, F (23)
Szummer, K (23)
Swahn, Eva (23)
Ohrvik, J (22)
Yusuf, S. (22)
Blomström-Lundqvist, ... (22)
Janszky, I (22)
Back, M (22)
Held, Claes (22)
Held, C (22)
Hage, C (22)
visa färre...
Lärosäte
Karolinska Institutet (1270)
Uppsala universitet (440)
Göteborgs universitet (239)
Lunds universitet (148)
Linköpings universitet (126)
Umeå universitet (124)
visa fler...
Kungliga Tekniska Högskolan (43)
Högskolan i Borås (40)
Örebro universitet (36)
Linnéuniversitetet (12)
Jönköping University (9)
Mälardalens universitet (6)
Högskolan Dalarna (6)
Högskolan i Halmstad (5)
Stockholms universitet (5)
Mittuniversitetet (5)
Handelshögskolan i Stockholm (4)
Högskolan Väst (3)
Malmö universitet (2)
Chalmers tekniska högskola (2)
Gymnastik- och idrottshögskolan (2)
Sveriges Lantbruksuniversitet (2)
Högskolan Kristianstad (1)
Högskolan i Gävle (1)
Högskolan i Skövde (1)
Röda Korsets Högskola (1)
visa färre...
Språk
Engelska (2139)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (761)
Teknik (9)
Samhällsvetenskap (6)
Lantbruksvetenskap (2)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy